Zebra Capital Management LLC bought a new stake in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 12,846 shares of the specialty pharmaceutical company’s stock, valued at approximately $81,000.

Other large investors have also recently modified their holdings of the company. Bank of Montreal Can grew its position in BioDelivery Sciences International by 42.4% during the fourth quarter. Bank of Montreal Can now owns 10,436 shares of the specialty pharmaceutical company’s stock worth $66,000 after buying an additional 3,108 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of BioDelivery Sciences International by 3.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 86,390 shares of the specialty pharmaceutical company’s stock worth $365,000 after acquiring an additional 3,160 shares during the period. Aigen Investment Management LP purchased a new position in BioDelivery Sciences International in the 4th quarter valued at approximately $27,000. California State Teachers Retirement System increased its stake in BioDelivery Sciences International by 3.7% in the 3rd quarter. California State Teachers Retirement System now owns 130,150 shares of the specialty pharmaceutical company’s stock valued at $548,000 after purchasing an additional 4,587 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in BioDelivery Sciences International by 14.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 44,800 shares of the specialty pharmaceutical company’s stock valued at $283,000 after purchasing an additional 5,500 shares in the last quarter. 71.30% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have commented on BDSI shares. ValuEngine upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Tuesday, February 25th. Piper Sandler assumed coverage on shares of BioDelivery Sciences International in a research report on Thursday, January 9th. They issued an “overweight” rating and a $9.00 price objective on the stock. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and set a $4.50 price objective on the stock. in a research report on Tuesday, March 10th. BidaskClub raised shares of BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 14th. Finally, SunTrust Banks raised their target price on shares of BioDelivery Sciences International from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $7.70.

Shares of NASDAQ BDSI traded up $0.20 during trading on Thursday, reaching $3.51. The company had a trading volume of 1,016,588 shares, compared to its average volume of 1,188,005. The company has a current ratio of 2.18, a quick ratio of 1.97 and a debt-to-equity ratio of 0.84. BioDelivery Sciences International, Inc. has a twelve month low of $2.85 and a twelve month high of $7.21. The stock has a 50-day moving average price of $4.59 and a two-hundred day moving average price of $5.38. The stock has a market capitalization of $326.66 million, a PE ratio of -18.47 and a beta of 0.46.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Thursday, March 12th. The specialty pharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. BioDelivery Sciences International had a positive return on equity of 13.41% and a negative net margin of 13.74%. The business had revenue of $31.60 million for the quarter, compared to analyst estimates of $30.10 million. On average, sell-side analysts predict that BioDelivery Sciences International, Inc. will post 0.22 EPS for the current year.

In other BioDelivery Sciences International news, insider Scott M. Plesha sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $5.77, for a total value of $86,550.00. Following the completion of the transaction, the insider now directly owns 192,336 shares in the company, valued at approximately $1,109,778.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $6.10, for a total value of $48,800.00. Following the completion of the transaction, the director now owns 556,754 shares of the company’s stock, valued at $3,396,199.40. The disclosure for this sale can be found here. Insiders have sold a total of 183,978 shares of company stock worth $923,980 over the last ninety days. 8.94% of the stock is owned by corporate insiders.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: Put Option Volume

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.